A phase 2 study of combination therapy with irinotecan/ S-1 (IRIS) plus panitumumab as second-line chemotherapy for metastatic colorectal cancer
- Conditions
- colonrectal cancer
- Registration Number
- JPRN-UMIN000004659
- Lead Sponsor
- The University of Tokushima Graduate School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 35
Not provided
1)Patients with the past history of severe allergic reactions 2)Patients with the past history of treatment of irinotecan and panitumumab 3) Patient with active double cancer 4)Patient with active infection 5) Patient with severe complications, such as paralytic ileus, bowel obstruction, interstitial pneumonitis, pulmonary fibrosis, or uncontrollable diabetes mellitus, arrhythmias, heart failure, liver cirrhosis, and active hepatitis) 6)Patients with severe interstitial pneumonitis or pulmonary fibrosis 7)Patients with uncontrollable ascites and pleural effusion 8)Patients with diarrhea 9) Patient with regular use of furucytocin or fenytoin 10)Patients with symptomatic brain metastasis 11) pregnant or nursing patient or with intent to bear baby 12) Exclude the patients who are recognized as inadequate patients by doctors with responsibility in this trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Completion rate of protocol therapy
- Secondary Outcome Measures
Name Time Method Response rate Overall survival Progression free survival Adverse events